Notícias · Recifes

AI-guided CRISPR uncovers oxytocin receptor as unexpected psoriasis drug target

Biohub researchers have performed what they believe is the first genome-wide CRISPR study of primary human adult skin cells, then used an AI model to mine the results for overlooked drug targets for psoriasis. They found an unlikely candidate: the receptor for oxytocin, a hormone

Admin Recifes 15/07/2026 2

Chromatin hubs help decide whether T cells fight chronic threats or fail

Chronic and viral infections can literally exhaust certain key cells in the immune system from a constant barrage of attacks. But a new pair of papers by scientists at the Hackensack Meridian Center for Discovery and Innovation (CDI) points to a way to understand how this exhaust

Admin Recifes 15/07/2026 2

Chlorhexidine blend wipes out 99.9% of Candida parapsilosis cells in lab tests

A 0.5% alcohol-based chlorhexidine antiseptic, combined with the natural organic compounds eugenol and menthol, can eliminate 99.9% of Candida parapsilosis cells. This fungus is one of the leading causes of infections in hospital settings, such as intensive care units (ICUs).

Admin Recifes 15/07/2026 2

Cellular 'bandages' help rebuild uterine lining after monthly shedding, study finds

For most women past puberty, the uterine lining (endometrium) sheds from the body roughly every month if there is no fertilized egg present. Then, the uterus rebuilds itself to prepare for a potential pregnancy. While this process—the menstrual cycle—is widely known, how it works

Admin Recifes 15/07/2026 2

Eight-patient Parkinson's stem cell clinical trial confirms feasibility

A landmark study led by Lund, Sweden, has shown that transplanting stem cell-derived dopamine progenitor cells into the brain is feasible. Eight patients were transplanted in the first clinical trial, and no serious side effects linked to the transplanted cells were seen during t

Admin Recifes 15/07/2026 2

New clinical data advances stem cell-based cell therapy for Parkinson's disease

New clinical data from the STEM-PD Phase I/II clinical trial have been presented at the ISSCR 2026 Annual Meeting. The study reports 12-month outcomes evaluating a cryopreserved, off-the-shelf dopaminergic progenitor cell product derived from human pluripotent stem cells for the

Admin Recifes 15/07/2026 2

Long-term stroke data reveal stem cell therapy's safety, biological activity over years

Previously unpublished long-term clinical and imaging findings from participants treated with an induced pluripotent stem cell (iPSC)-derived neural progenitor cell therapy for chronic ischemic stroke were presented at the ISSCR 2026 Annual Meeting.

Admin Recifes 15/07/2026 2

New data highlight off-the-shelf iPSC-derived CAR T-cell therapy for treatment-resistant s

New preliminary clinical data presented at ISSCR 2026 evaluated an induced pluripotent stem cell (iPSC)-derived CAR T-cell therapy for patients with treatment-resistant systemic sclerosis, a rare autoimmune disease with high mortality.

Admin Recifes 15/07/2026 2

Data highlight progress toward personalized stem cell therapy for Parkinson's disease

Interim clinical findings from the first Phase I/IIa trial using autologous-induced pluripotent stem cell (iPSC)-derived dopamine neuron precursor cells, along with the novel quality-control tools developed to manufacture these individualized therapies, have been presented by Jea

Admin Recifes 15/07/2026 2

Huntington's treatment quest reaches first pluripotent stem cell trial, with safety now un

An update on the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington's disease was presented at the ISSCR 2026 Annual Meeting. The Phase Ib/IIa REGEN4HD study represents a significant translational milestone following years of p

Admin Recifes 15/07/2026 2

Data demonstrate 1-year survival of stem cell-derived neural progenitor cells in patients

New, previously unpublished clinical data have been presented at ISSCR 2026 demonstrating that transplanted human neural progenitor cells survived for at least one year following subretinal transplantation in patients with retinitis pigmentosa (RP), while maintaining a favorable

Admin Recifes 15/07/2026 2

FDA expands use of first sickle cell disease gene therapy for children as young as 2 years

The U.S. Food and Drug Administration has issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients ages 2 and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β thalassemia (TDT). Supplement

Admin Recifes 15/07/2026 2

Acompanhe as Notícias da Recifes